Skip to main content
. 2017 Jan 9;8(1):115–128. doi: 10.1007/s13300-016-0224-5

Fig. 1.

Fig. 1

Kaplan-Meier analyses for time to stop: a exBID; b LIRA; c exQW; d LIXI. BE Belgium, exBID exenatide twice daily, exQW exenatide once weekly, FR France; DE Germany, LIRA liraglutide, LIXI lixisenatide, NL The Netherlands, SE Sweden